Targovax
ISIN: NO0010689326 | Ticker: TRVX | LEI: 5967007LIEEXZXFYNS31
Country: Norway
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
2010
Served areaWorldwide
HeadquartersVollsveien 19, 1366 Lysaker – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 520,740,000.00 | 565,271,000.00 | 100,414,000.00 |
| Noncurrent Assets | N/A | 393,559,000.00 | 374,382,000.00 | 6,302,000.00 |
| Property Plant And Equipment | N/A | 179,000.00 | 111,000.00 | 5,035,000.00 |
| Current Assets | N/A | 127,180,000.00 | 190,889,000.00 | 94,112,000.00 |
| Trade And Other Current Receivables | N/A | 4,859,000.00 | 9,207,000.00 | 28,097,000.00 |
| Cash and cash equivalents | 70,429,000.00 | 122,321,000.00 | 181,682,000.00 | 66,015,000.00 |
| Equity And Liabilities | N/A | 520,740,000.00 | 565,271,000.00 | 100,414,000.00 |
| Equity | 296,955,000.00 | 372,588,000.00 | 417,726,000.00 | 2,566,000.00 |
| Issued Capital | N/A | 8,653,000.00 | 18,833,000.00 | 18,847,000.00 |
| Retained Earnings | N/A | -778,136,000.00 | 309,289,000.00 | -123,672,000.00 |
| Share Premium | N/A | 1,046,476,000.00 | 0.00 | N/A |
| Other Reserves | N/A | 52,684,000.00 | 59,620,000.00 | 63,780,000.00 |
| Noncurrent Liabilities | N/A | 122,495,000.00 | 110,212,000.00 | 57,433,000.00 |
| Deferred Tax Liabilities | N/A | 62,047,000.00 | 59,314,000.00 | N/A |
| Longterm Borrowings | N/A | 57,881,000.00 | 49,523,000.00 | 57,433,000.00 |
| Current Liabilities | N/A | 25,656,000.00 | 37,333,000.00 | 40,415,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 5,196,000.00 | 8,103,000.00 | 11,383,000.00 |
| Current Payables On Social Security And Taxes Other Than Income Tax | N/A | 3,428,000.00 | 3,203,000.00 | 3,074,000.00 |
| Other Current Liabilities | N/A | 12,589,000.00 | 17,134,000.00 | 19,971,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 624,000.00 | 0.00 | 10,002,000.00 |
| Other Revenue | 624,000.00 | 0.00 | 10,002,000.00 |
| Employee Benefits Expense | 43,090,000.00 | 48,386,000.00 | 52,238,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 3,735,000.00 | 1,309,000.00 | 392,673,000.00 |
| Other Expense By Nature | 12,658,000.00 | 8,466,000.00 | 11,454,000.00 |
| Profit Loss From Operating Activities | -103,901,000.00 | -95,601,000.00 | -493,591,000.00 |
| Finance Income | 596,000.00 | 245,000.00 | 3,360,000.00 |
| Finance Costs | 5,099,000.00 | 2,667,000.00 | 5,097,000.00 |
| Profit Loss Before Tax | -108,403,000.00 | -98,023,000.00 | -495,328,000.00 |
| Income Tax Expense Continuing Operations | -277,000.00 | -52,000.00 | -62,430,000.00 |
| Profit (loss) | -108,126,000.00 | -97,971,000.00 | -432,898,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -108,126,000.00 | -97,971,000.00 | -432,898,000.00 |
| Adjustments For Finance Costs | N/A | 5,099,000.00 | 2,667,000.00 | 5,097,000.00 |
| Adjustments For Sharebased Payments | N/A | 5,799,000.00 | 6,935,000.00 | 4,160,000.00 |
| Interest Received Classified As Operating Activities | N/A | 596,000.00 | 245,000.00 | 536,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -110,793,000.00 | -85,402,000.00 | -108,841,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 70,000.00 | 0.00 | 4,935,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | N/A | 24,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -70,000.00 | 0.00 | -4,959,000.00 |
| Proceeds From Issuing Shares | N/A | 176,021,000.00 | 175,000,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 5,555,000.00 | 0.00 | N/A |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 2,023,000.00 | 2,086,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,209,000.00 | 1,468,000.00 | 1,515,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 704,000.00 | 710,000.00 | 680,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 163,534,000.00 | 145,610,000.00 | -4,328,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 52,671,000.00 | 60,208,000.00 | -118,129,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -778,000.00 | -848,000.00 | 2,462,000.00 |
| Cash and cash equivalents | 70,429,000.00 | 122,321,000.00 | 181,682,000.00 | 66,015,000.00 |
Please note that some sums might not add up.
NO0010689326
LEI5967007LIEEXZXFYNS31
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.